Your browser doesn't support javascript.
loading
Second allo-SCT in patients with lymphoma relapse after a first allogeneic transplantation. A retrospective study of the EBMT Lymphoma Working Party.
Horstmann, K; Boumendil, A; Finke, J; Finel, H; Kanfer, E; Milone, G; Russell, N; Bacigalupo, A; Chalandon, Y; Diez-Martin, J L; Ifrah, N; Chacon, M Jurado; Dreger, P.
Afiliação
  • Horstmann K; 1] EBMT Lymphoma Working Party, Paris, France [2] Department of Medicine V, University of Heidelberg, Heidelberg, Germany.
  • Boumendil A; EBMT Lymphoma Working Party, Paris, France.
  • Finke J; Department of Medicine I, University of Freiburg, Freiburg, Germany.
  • Finel H; EBMT Lymphoma Working Party, Paris, France.
  • Kanfer E; Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • Milone G; Programma di Trapianto Emopoietico, Azienda Ospedaliera Policlinico Vittorio Emanuele, Catania, Italy.
  • Russell N; Center for Clinical Hematology, Nottingham University Hospital, Nottingham, UK.
  • Bacigalupo A; Division of Hematology and Bone Marrow Transplantation, IRCCS San Martino, Genova, Italy.
  • Chalandon Y; 1] Division of Hematology, Department of Medical Specialties, University Hospital, Geneva, Switzerland [2] Faculty of Medicine, University of Geneva, Geneva, Switzerland.
  • Diez-Martin JL; Department of Hematology and Hemotherapy, HGU Gregorio Marañón, Madrid, Spain.
  • Ifrah N; CHRU, Service des Maladies du Sang, Angers, France.
  • Chacon MJ; Hospital Universitario "Virgen de las Nieves", Granada, Spain.
  • Dreger P; 1] EBMT Lymphoma Working Party, Paris, France [2] Department of Medicine V, University of Heidelberg, Heidelberg, Germany.
Bone Marrow Transplant ; 50(6): 790-4, 2015 Jun.
Article em En | MEDLINE | ID: mdl-25751644
ABSTRACT
The aim of this registry-based retrospective study was to analyze the outcome of second allogeneic hematopoietic SCT (alloHSCT_2) performed in patients with lymphoma who had relapsed after a first allogeneic transplant (alloHSCT_1). Patients ⩾18 years who had received an alloHSCT_2 for lymphoma relapse between 2000 and 2011 were eligible. One hundred and forty patients were identified. The diagnosis was Hodgkin lymphoma (HL) in 31%, diffuse large B-cell lymphoma in 14%, T-cell lymphoma in 12%, indolent lymphoma in 19%, mantle cell lymphoma in 16% and other lymphomas in 8% of the patients. The median interval from alloHSCT_1 to alloHSCT_2 was 19 (range 4-116) months. Disease status at alloHSCT_2 was chemosensitive in 46%, refractory in 43% and unknown in 11% of the patients. Three-year PFS, OS, relapse incidence and nonrelapse mortality were 19%, 29%, 58% and 23%, respectively. PFS and OS were significantly affected by refractory disease at alloHSCT_2 and a short interval between alloHSCT_1 and alloHSCT_2. Long-term PFS was observed across all lymphoma subsets except for aggressive B-cell lymphoma. In conclusion, alloHSCT_2 is feasible and can result in long-term disease control in patients with lymphoma recurrence after alloHSCT_1, in particular if relapse occurs late and is chemosensitive.
Assuntos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Transplante de Células-Tronco / Linfoma Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Bone Marrow Transplant Assunto da revista: TRANSPLANTE Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Transplante de Células-Tronco / Linfoma Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Bone Marrow Transplant Assunto da revista: TRANSPLANTE Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Alemanha